Free Trial

Recursion Pharmaceuticals (RXRX) Earnings Date, Estimates & Call Transcripts

Recursion Pharmaceuticals logo
$6.18 -0.74 (-10.70%)
(As of 11/15/2024 ET)

Recursion Pharmaceuticals Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 25Estimated
Actual EPS
(Nov. 6)
-$0.34 Missed By -$0.01
Consensus EPS
(Nov. 6)
-$0.33

Recursion Pharmaceuticals released Q3 2024 earnings on November 6, 2024, reporting an EPS of -$0.34, which missed analysts' consensus estimates of -$0.33 by $0.01. Quarterly revenue rose 147.6% year-over-year to $26.08 million, above the consensus estimate of $12.62 million. With a trailing EPS of -$1.53, Recursion Pharmaceuticals' earnings are expected to grow next year, from ($1.56) to ($1.42) per share.

RXRX Upcoming Earnings

Recursion Pharmaceuticals' next earnings date is estimated for Tuesday, February 25, 2025, based off prior year's reporting schedules.

Get Recursion Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Recursion Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

RXRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RXRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Recursion Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242-$0.41-$0.33-$0.37
Q2 20242-$0.41-$0.33-$0.37
Q3 20242-$0.41-$0.35-$0.38
Q4 20242-$0.83-$0.33-$0.58
FY 20248($2.06)($1.34)($1.70)

Recursion Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/25/2025
(Estimated)
------- 
11/6/2024Q3 2024-$0.33-$0.34 -$0.01-$0.34$12.62M$26.08M  
8/8/2024Q2 2024-$0.35-$0.40 -$0.05-$0.40$11.96M$14.42M          
5/9/2024Q1 2024-$0.43-$0.39+$0.04-$0.39$11.10M$13.80M      
2/27/2024Q4 2023-$0.46-$0.40+$0.06-$0.40$12.37M$10.89M  
11/9/2023Q3 2023-$0.38-$0.43 -$0.05-$0.43$12.20M$10.53M  
8/8/2023Q2 2023-$0.38-$0.38--$0.38$10.43M$11.02M  
5/8/2023Q1 2023-$0.35-$0.34+$0.01-$0.34$15.93M$12.13M  
2/27/2023Q4 2022-$0.15-$0.31 -$0.16-$0.31$66.68M$13.68M  

Recursion Pharmaceuticals Earnings - Frequently Asked Questions

Recursion Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates. Learn more on RXRX's earnings history.

In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.33) by $0.01 with a reported earnings per share (EPS) of ($0.34). Learn more on analysts' earnings estimate vs. RXRX's actual earnings.

Recursion Pharmaceuticals's earnings report can be found in their filing with the SEC.
View SEC filing

Recursion Pharmaceuticals (NASDAQ:RXRX) has a recorded annual revenue of $44.58 million.

Recursion Pharmaceuticals (NASDAQ:RXRX) has a recorded net income of -$328.07 million. RXRX has generated -$1.53 earnings per share over the last four quarters.

Recursion Pharmaceuticals's earnings are expected to grow from ($1.56) per share to ($1.42) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:RXRX) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners